Powerful drug duo slows kidney cancer progression in major trial
NCT ID NCT02853331
First seen Feb 02, 2026 · Last updated May 06, 2026 · Updated 12 times
Summary
This study tested a combination of two drugs (pembrolizumab and axitinib) against the standard single drug (sunitinib) in 861 people with advanced kidney cancer that had spread. The goal was to see if the combo could help people live longer and keep the cancer from growing. Results showed the combo improved both survival and time without cancer worsening, offering a new first-line option for patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.